Even though sugammadex has been proposed as one of the solutions to avoid residual block, the pharmacokinetic alterations occuring in patients with chronic renal disease supossedly decreasing its clearance, this benefit may not be extensive to them. However, as shown in this case and in other studies, recovery time is similar to patients without renal disease. 2. Jones EA, Neuberger J. Bergasa NV.
Aunque el sugammadex se ha propuesto como una de las posibles soluciones para la prevención de la relajación residual, las alteraciones farmacocinéticas que ocurren en los pacientes con enfermedad renal crónica debidas a su mecanismo de eliminación hacen que este beneficio no sea extensivo a este grupo poblacional.